恩替卡韦联合奥曲肽在肝炎患者中的应用

Application of Effecavir Combined With Octreotide in Patients With Hepatitis

目的探讨恩替卡韦联合奥曲肽在肝炎患者中的应用。方法选择2018年5月—2019年5月收治的120例肝炎治疗患者,随机分为对照组和研究组,对照组应用恩替卡韦治疗,研究组应用恩替卡韦联合奥曲肽治疗,对比两组患者在治疗后的效果及ADL评分。结果研究组治疗10周、12周后肝炎病毒未转阴的例数低于对照组(P<0.05)。研究组患者治疗8周、12周后的ADL评分改善均优于对照组(P<0.05)。结论肝炎的治疗过程当中,恩替卡韦联合奥曲肽的治疗效果更理想,在治疗相同时间后,患者肝炎病毒的转阴效果更好,加快了患者的恢复。而且有效的提高了患者治疗后的日常生活能力,改善ADL评分。

Objective To investigate the effect of entecavir combined with octreotide in patients with hepatitis and its effect on ADL score.Methods A total of 120 hepatitis patients admitted from May 2018 to May 2019 were selected and randomly divided into control group and study group.The control group was treated with entecavir,while the study group was treated with entecavir combined with octreotide.The effect of treatment and ADL score were compared between the two groups.Results After 10 weeks and 12 weeks of treatment,the number of cases in the study group was lower than that in the control group(P<0.05).The ADL score of the study group was better than that of the control group after 8 weeks and 12 weeks(P<0.05).Conclusion In the treatment of hepatitis,entecavir combined with octreotide has a better therapeutic effect.After the same time of treatment,the patient has a better negative effect of hepatitis virus,which speeds up the recovery of the patient.Moreover,it effectively improves the daily living ability of patients after treatment and improves the ADL score,which should be further popularized and applied in clinical practice.